A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting

NCT ID: NCT02413008

Last Updated: 2019-08-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 61 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-10-16
• Study Completion Date: 2017-02-10

Brief Summary

This is a phase II, prospective, randomized, double-blind, placebo-controlled, international (Spain and Sweden) and multicentre study to explore the safety of 0.005% estriol vaginal gel in women with early stage breast cancer in treatment with Non-Steroidal Aromatase Inhibitors (NSAIs) in the adjuvant setting and symptoms of vaginal atrophy.

Detailed Description

This is a phase II, prospective, randomized, double-blind, placebo-controlled, international (Spain and Sweden) and multicentre study.

In the setting of postmenopausal hormone receptor positive breast cancer, treatment with aromatase inhibitors (AIs) is the most effective and well-studied therapy. Vaginal dryness is one of the most frequently reported symptom caused by this adjuvant therapy which may lead to a reduced adherence in breast cancer women.

This study will explore the safety of 0.005% estriol vaginal gel in this oncological context, to demonstrate that this medicinal product is a safe option to treat the vaginal atrophy caused by AIs, without a clinically relevant influence in gonadotropins or systemic estrogen levels.

The main objective is to evaluate the levels of Follicle Stimulating Hormone (FSH) after treatment with 0.005% estriol vaginal gel in hormone receptor-positive postmenopausal women with early stage breast cancer in treatment with Non-Steroidal Aromatase Inhibitors (NSAIs) in the adjuvant setting and symptoms of vaginal atrophy.

Conditions

Vaginal Atrophy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

0.005% estriol vaginal gel

Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration

Group Type: EXPERIMENTAL

estriol

Intervention Type: DRUG

0.005% estriol vaginal gel

placebo vaginal gel

Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

placebo vaginal gel

Interventions

estriol

0.005% estriol vaginal gel

Intervention Type: DRUG

Placebo

placebo vaginal gel

Intervention Type: DRUG

Other Intervention Names

Blissel (estriol); Gelistrol (estriol)

Eligibility Criteria

Inclusion Criteria

1. Written informed consent prior to beginning specific protocol procedures.

2. Patients must have histological confirmation of breast adenocarcinoma with stage I-IIIA, documented at a local pathology department.

3. The breast tumors must be estrogen-receptor positive and/or progesterone receptor positive (≥1% of stained tumor cells by Immunohistochemistry (IHC) as determined by the local laboratory) with any Human Epidermal Growth Factor Receptor 2(HER2) status.

4. Postmenopausal status defined as: 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 Milli-international units per milliliter (mIU/ml) or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.

5. Patient must be receiving the non-steroidal aromatase inhibitors anastrozole or letrozole as breast cancer treatment in the adjuvant setting for a minimum of 6 months.

6. Women suffering from moderate to severe vaginal dryness according to the FDA guidelines for drug development in postmenopausal women (Center for Drug Evaluation and Research, (CDER) Jan 2003). A moderate symptom will be considered if the symptom is present, bothersome and annoying, and a severe symptom will be considered if the symptom is present, bothersome and annoying, and interferes with the normal patient activity.

7. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.

8. Adequate bone marrow as defined by the following laboratory values:

1. Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L.

2. Platelets (plt) ≥ 100 x 109/L.

3. Hemoglobin (Hgb) ≥ 10 g/dl.

9. Patient has adequate organ function as defined by the following laboratory values:

1. Serum creatinine ≤ 1.5 x Upper Limit of Normal (ULN).

2. Bilirubin ≤ 1.5 × ULN.

3. Alkaline phosphatase ≤ 2 × ULN.

4. Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2 × ULN.

10. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion Criteria

1. Stage IIIB-IV breast cancer or bilateral breast cancer.

2. Treatment with any other current anti-tumoral therapy (chemotherapy, anti-Her2…etc) besides the NSAI. Pamidronate or Alendronate are permitted.

3. Prior history of other malignancy within 5 years of study entry, aside from non-melanoma skin cancer or carcinoma-in-situ of the uterine cervix adequately treated.

4. Postmenopausal uterine bleeding. Vaginal bleeding of unknown etiology.

5. Patients with endometrial thickness equal to or greater than 4 mm measured by transvaginal ultrasound.

6. Patients who have received any type of vulvovaginal treatment in the 15 days prior to the start of the study.

7. Use of any hormone, natural (phytoestrogens) or herbal products for the treatment of menopausal symptoms within the last 3 months.

8. Current or previous history of thromboembolic disease or coagulopathies.

9. Severe cardiovascular or respiratory diseases in the previous 6 months.

10. Renal Impairment.

11. Hepatitis B and/or hepatitis C carriers (unless with normal hepatic function).

12. Known human immunodeficiency virus infection.

13. Known hypersensitivity to NSAI.

14. Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

15. Previous investigational treatment for any condition or participation in any clinical trial within 4 weeks of inclusion date.

• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Spanish Breast Cancer Research Group

OTHER

Sponsor Role: collaborator

ITF Research Pharma, S.L.U.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U.

L'Hospitalet de Llobregat, Barcelona, Spain

For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U.

A Coruña, , Spain

For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U.

Jaén, , Spain

For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U.

Madrid, , Spain

For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U.

Valencia, , Spain

For additional information regarding investigative sites for this trial, contact ITF Research Pharma S.L.U.

Stockholm, , Sweden

Countries

Spain; Sweden

References

Sanchez-Rovira P, Hirschberg AL, Gil-Gil M, Bermejo-De Las Heras B, Nieto-Magro C. A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting. Oncologist. 2020 Dec;25(12):e1846-1854. doi: 10.1634/theoncologist.2020-0417. Epub 2020 Jun 9.

Reference Type: DERIVED

PMID: 32459035 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

2014-004517-84

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

ITFE-2026-C10

Identifier Type: -

Identifier Source: org_study_id